-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation

PUBT·04/21/2026 14:01:42
Listen to the news
Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
  • Cellectar Biosciences set a CLOVER-WaM subgroup data update on iopofosine I-131 for presentation at ASCO 2026 on June 1.
  • Disclosure targets relapsed or refractory Waldenström macroglobulinemia patients who progressed on BTK inhibitors.
  • Management characterized iopofosine safety profile as encouraging.
  • Company also described efficacy signals as supportive of a differentiated post-BTK inhibitor option, potentially as early as second-line use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211000PRIMZONEFULLFEED9693634) on April 21, 2026, and is solely responsible for the information contained therein.